{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:59:11Z","timestamp":1785369551795,"version":"3.55.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ecl.2026.04.002","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T20:20:42Z","timestamp":1779135642000},"page":"421-435","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Daily Glucagon-like Peptide-1 Receptor Agonists in Type 1 Diabetes"],"prefix":"10.1016","volume":"55","author":[{"given":"Rachael","family":"Innes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Petrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Fremming","family":"Dejgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ecl.2026.04.002_bib1","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.2337\/diacare.24.10.1711","article-title":"Influence of intensive diabetes treatment on body weight and composition of adults with type 1 diabetes in the diabetes control and complications trial","volume":"24","year":"2001","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.ecl.2026.04.002_bib2","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(21)00246-1","article-title":"Obesity in people living with type 1 diabetes","volume":"9","author":"Van der Schueren","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"10.1016\/j.ecl.2026.04.002_bib3","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nrendo.2012.140","article-title":"GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus","volume":"8","author":"Meier","year":"2012","journal-title":"Nat Rev Endocrinol"},{"issue":"12","key":"10.1016\/j.ecl.2026.04.002_bib4","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.2337\/dc15-1037","article-title":"Twelve-week treatment with liraglutide as Add-on to insulin in normal-weight patients with poorly controlled type 1 diabetes: a randomized, placebo-controlled, double-blind parallel study","volume":"38","author":"Frandsen","year":"2015","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.ecl.2026.04.002_bib5","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S2213-8587(15)00436-2","article-title":"Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial","volume":"4","author":"Dejgaard","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"10.1016\/j.ecl.2026.04.002_bib6","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.2337\/dc16-0691","article-title":"Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the ADJUNCT ONE treat-to-target randomized trial","volume":"39","author":"Mathieu","year":"2016","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.ecl.2026.04.002_bib7","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1210\/jc.2016-1451","article-title":"Dapagliflozin as additional treatment to liraglutide and insulin in patients with type 1 diabetes","volume":"101","author":"Kuhadiya","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.ecl.2026.04.002_bib8","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/dom.13911","article-title":"Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin-pump-treated patients with type 1 diabetes: the Lira pump trial\u2014a randomized, double-blinded, placebo-controlled trial","volume":"22","author":"Dejgaard","year":"2020","journal-title":"Diabetes Obes Metabol"},{"issue":"4","key":"10.1016\/j.ecl.2026.04.002_bib9","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S2213-8587(20)30030-9","article-title":"Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial","volume":"8","author":"Johansen","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"10.1016\/j.ecl.2026.04.002_bib10","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.1111\/dom.15889","article-title":"Liraglutide enhances insulin secretion and prolongs the remission period in adults with newly diagnosed type 1 diabetes (the NewLira study): a randomized, double-blind, placebo-controlled trial","volume":"26","author":"Dejgaard","year":"2024","journal-title":"Diabetes Obes Metabol"},{"issue":"9","key":"10.1016\/j.ecl.2026.04.002_bib11","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/S2213-8587(16)00039-5","article-title":"Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus","volume":"4","author":"Frandsen","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"10.1016\/j.ecl.2026.04.002_bib12","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.2337\/db10-1790","article-title":"Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual \u03b2-cell function","volume":"60","author":"Kielgast","year":"2011","journal-title":"Diabetes"},{"issue":"10","key":"10.1016\/j.ecl.2026.04.002_bib13","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.ecl.2026.04.002_bib14","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.2337\/diabetes.54.6.1615","article-title":"The pathobiology of diabetic complications: a unifying mechanism","volume":"54","author":"Brownlee","year":"2005","journal-title":"Diabetes"},{"issue":"10","key":"10.1016\/j.ecl.2026.04.002_bib15","doi-asserted-by":"crossref","first-page":"5432","DOI":"10.1111\/dom.16606","article-title":"The Steno 1 study: multifactorial intervention to reduce cardiovascular disease in type 1 diabetes-rationale and protocol of the prospective, randomized, open-labelled multicentre study","volume":"27","author":"Stougaard","year":"2025","journal-title":"Diabetes Obes Metabol"},{"issue":"10","key":"10.1016\/j.ecl.2026.04.002_bib16","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.2337\/dc16-0690","article-title":"Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes: the ADJUNCT TWO randomized trial","volume":"39","author":"Ahr\u00e9n","year":"2016","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.ecl.2026.04.002_bib17","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2337\/dc15-1136","article-title":"Addition of liraglutide to insulin in patients with type 1 diabetes: a randomized placebo-controlled clinical trial of 12 weeks","volume":"39","author":"Kuhadiya","year":"2016","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.ecl.2026.04.002_bib18","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1111\/dom.14090","article-title":"Liraglutide treatment in overweight and obese patients with type 1 diabetes: a 26-week randomized controlled trial; mechanisms of weight loss","volume":"22","author":"Ghanim","year":"2020","journal-title":"Diabetes Obes Metabol"},{"issue":"4","key":"10.1016\/j.ecl.2026.04.002_bib19","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S2213-8587(21)00019-X","article-title":"Anti-interleukin-21 antibody and liraglutide for the preservation of \u03b2-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"9","author":"von Herrath","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.ecl.2026.04.002_bib20","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/dom.14567","article-title":"Liraglutide changes body composition and lowers added sugar intake in overweight persons with insulin pump-treated type 1 diabetes","volume":"24","author":"Schmidt","year":"2022","journal-title":"Diabetes Obes Metabol"},{"issue":"2","key":"10.1016\/j.ecl.2026.04.002_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3212","article-title":"Liraglutide combined with human umbilical cord mesenchymal stem cell transplantation inhibits beta-cell apoptosis via mediating the ASK1\/JNK\/BAX pathway in rats with type 2 diabetes","volume":"36","author":"Wang","year":"2020","journal-title":"Diabetes Metab Res Rev"},{"issue":"1","key":"10.1016\/j.ecl.2026.04.002_bib22","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1210\/clinem\/dgad471","article-title":"Glucagon-Like peptide 1 analogues as adjunctive therapy for patients with type 1 diabetes: an updated systematic review and meta-analysis","volume":"109","author":"Park","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"21","key":"10.1016\/j.ecl.2026.04.002_bib23","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1001\/jama.2015.16174","article-title":"Effect of metformin added to insulin on glycemic control among overweight\/obese adolescents with type 1 diabetes: a randomized clinical trial","volume":"314","author":"Libman","year":"2015","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.ecl.2026.04.002_bib24","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S2213-8587(17)30194-8","article-title":"Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial","volume":"5","author":"Petrie","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"10.1016\/j.ecl.2026.04.002_bib25","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S2213-8587(17)30315-7","article-title":"SGLT2 inhibitors in type 1 diabetes: knocked Down, but up again?","volume":"5","author":"Petrie","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"Supplement_1","key":"10.1016\/j.ecl.2026.04.002_bib26","doi-asserted-by":"crossref","DOI":"10.2337\/db25-785-P","article-title":"785-P: first report on the small molecule oral GLP-1 receptor agonist RGT-075 in obesity\u2014A randomized, placebo-controlled phase 2a proof-of-concept twelve-week study","volume":"74","author":"Rosenstock","year":"2025","journal-title":"Diabetes"},{"key":"10.1016\/j.ecl.2026.04.002_bib27","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.2147\/DMSO.S439587","article-title":"Evaluating glycemic control efficacy and safety of the oral small molecule glucagon-like peptide 1 receptor agonist danuglipron in type 2 diabetes patients: a systemic review and meta-analysis","volume":"16","author":"Fatima","year":"2023","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"3","key":"10.1016\/j.ecl.2026.04.002_bib28","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.3390\/ijms27031409","article-title":"Orforglipron: a comprehensive review of an oral small-molecule GLP-1 receptor agonist for obesity and type 2 diabetes","volume":"27","author":"Kansakar","year":"2026","journal-title":"Int J Mol Sci"},{"issue":"10522","key":"10.1016\/j.ecl.2026.04.002_bib29","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1016\/S0140-6736(25)02381-5","article-title":"Oral small-molecule GLP-1 receptor agonist for type 2 diabetes and obesity","volume":"406","author":"Chow","year":"2025","journal-title":"Lancet"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985292600023X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985292600023X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:25:29Z","timestamp":1785367529000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S088985292600023X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S088985292600023X"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2026.04.002","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Daily Glucagon-like Peptide-1 Receptor Agonists in Type 1 Diabetes","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2026.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}